Clinical significance of the nuclear receptor co-regulator DC-SCRIPT in breast cancer: An independent retrospective validation study

Breast Cancer Research

Volumn 12, Issue 6, 2010, Pages

  Sieuwerts, Anieta M ^a   Ansems, Marleen ^b   Look, Maxime P ^a   Span, Paul N ^c   de Weerd, Vanja ^a   van Galen, Anne ^a   Foekens, John A ^a   Adema, Gosse J ^b   Martens, John W M ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; DC SCRIPT PROTEIN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MESSENGER RNA; REGULATOR PROTEIN; TAMOXIFEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; ESTROGEN RECEPTOR; TUMOR MARKER; ZNF366 PROTEIN, HUMAN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INVASION; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EVALUATION; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; VALIDATION STUDY; BREAST TUMOR; GENE EXPRESSION; GENETICS; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARRIER PROTEINS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM METASTASIS; POLYMERASE CHAIN REACTION; PROGNOSIS; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; RNA, MESSENGER; TAMOXIFEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 78649527573     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2786     Document Type: Article

References (28)

1. Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA. Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA 2004, 101:1566-1571. 10.1073/pnas.0308319100, 341775, 14745018.
2. Liu MM, Albanese C, Anderson CM, Hilty K, Webb P, Uht RM, Price RH, Pestell RG, Kushner PJ. Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J Biol Chem 2002, 277:24353-24360. 10.1074/jbc.M201829200, 11986316.
3. Hartman J, Strom A, Gustafsson JA. Estrogen receptor beta in breast cancer--diagnostic and therapeutic implications. Steroids 2009, 74:635-641. 10.1016/j.steroids.2009.02.005, 19463683.
4. Triantis V, Moulin V, Looman MW, Hartgers FC, Janssen RA, Adema GJ. Molecular characterization of the murine homologue of the DC-derived protein DC-SCRIPT. J Leukoc Biol 2006, 79:1083-1091. 10.1189/jlb.1005588, 16522745.
5. Triantis V, Trancikova DE, Looman MW, Hartgers FC, Janssen RA, Adema GJ. Identification and characterization of DC-SCRIPT, a novel dendritic cell-expressed member of the zinc finger family of transcriptional regulators. J Immunol 2006, 176:1081-1089.
6. Lopez-Garcia J, Periyasamy M, Thomas RS, Christian M, Leao M, Jat P, Kindle KB, Heery DM, Parker MG, Buluwela L, Kamalati T, Ali S. ZNF366 is an estrogen receptor corepressor that acts through CtBP and histone deacetylases. Nucleic Acids Res 2006, 34:6126-6136. 10.1093/nar/gkl875, 1693901, 17085477.
7. Ansems M, Hontelez S, Looman MW, Karthaus N, Bult P, Bonenkamp JJ, Jansen JH, Sweep FC, Span PN, Adema GJ. DC-SCRIPT: nuclear receptor modulation and prognostic significance in primary breast cancer. J Natl Cancer Inst 2010, 102:54-68. 10.1093/jnci/djp441, 20008677.
8. Ramadoss P, Marcus C, Perdew GH. Role of the aryl hydrocarbon receptor in drug metabolism. Expert Opin Drug Metab Toxicol 2005, 1:9-21. 10.1517/17425255.1.1.9, 16922649.
9. Osborne CK, Schiff R, Fuqua SA, Shou J. Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res 2001, 7:4338s-4342s. discussion 4411s-4412s.
10. Code of Conduct of the Federation of Medical Scientific Societies in the Netherlands. , http://www.federa.org/?s=1&m=99
11. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 2006, 100:229-235. 10.1007/s10549-006-9242-8, 16932852.
12. Jansen MP, Sieuwerts AM, Look MP, Ritstier K, Meijer-van ME, van Staveren IL, Klijn JG, Foekens JA, Berns EM. HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study. J Clin Oncol 2007, 25:662-668. 10.1200/JCO.2006.07.3676, 17308270.
13. Sieuwerts AM, Look MP, Meijer-van ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, de Weerd V, Portengen H, Klijn JG, Foekens JA. Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients. Clin Cancer Res 2006, 12:3319-3328. 10.1158/1078-0432.CCR-06-0225, 16740753.
14. Sieuwerts AM, Usher PA, Meijer-van ME, Timmermans M, Martens JW, Brunner N, Klijn JG, Offenberg H, Foekens JA. Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer. Clin Chem 2007, 53:1280-1288. 10.1373/clinchem.2006.082800, 17478562.
15. Foekens JA, Portengen H, van Putten WL, Peters HA, Krijnen HL, Alexieva-Figusch J, Klijn JG. Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res 1989, 49:5823-5828.
16. Sieuwerts AM, Meijer-van ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, Portengen H, Klijn JG, Foekens JA. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study. Clin Cancer Res 2005, 11:7311-7321. 10.1158/1078-0432.CCR-05-0560, 16243802.
17. Dorssers LC, van Agthoven T, Brinkman A, Veldscholte J, Smid M, Dechering KJ. Breast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor signalling pathway. Breast Cancer Res 2005, 7:R82-92. 10.1186/bcr954, 1064102, 15642172.
18. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer 1977, 39:1289-1294. 10.1002/1097-0142(197703)39:3<1289::AID-CNCR2820390340>3.0.CO;2-F, 912660.
19. Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijer-van ME, Geurts-Moespot A, van der Kwast TH, Sweep CG, Klijn JG. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 2001, 61:5407-5414.
20. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA, Martens JW. Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008, 68:3108-3114. 10.1158/0008-5472.CAN-07-5644, 18451135.
21. Lee LM, Cao J, Deng H, Chen P, Gatalica Z, Wang ZY. ER-alpha36, a novel variant of ER-alpha, is expressed in ER-positive and -negative human breast carcinomas. Anticancer Res 2008, 28:479-483. 2610490, 18383888.
22. Chen JQ, Russo PA, Cooke C, Russo IH, Russo J. ERbeta shifts from mitochondria to nucleus during estrogen-induced neoplastic transformation of human breast epithelial cells and is involved in estrogen-induced synthesis of mitochondrial respiratory chain proteins. Biochim Biophys Acta 2007, 1773:1732-1746. 10.1016/j.bbamcr.2007.05.008, 17604135.
23. Shaaban AM, Green AR, Karthik S, Alizadeh Y, Hughes TA, Harkins L, Ellis IO, Robertson JF, Paish EC, Saunders PT, Groome NP, Speirs V. Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res 2008, 14:5228-5235. 10.1158/1078-0432.CCR-07-4528, 18698041.
24. Jansen MP, Foekens JA, Klijn JG, Berns EM. Re: Limits of predictive models using microarray data for breast cancer clinical treatment outcome. J Natl Cancer Inst 2005, 97:1851-1852. author reply 1852-1853, 10.1093/jnci/dji433, 16368948.
25. Foekens JA, Look MP, Bolt-de J, Meijer-van ME, van Putten WL, Klijn JG. Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients. Br J Cancer 1999, 79:300-307. 10.1038/sj.bjc.6690048, 2362199, 9888472.
26. van Agthoven T, Sieuwerts AM, Meijer-van ME, Look MP, Smid M, Veldscholte J, Sleijfer S, Foekens JA, Dorssers LC. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J Clin Oncol 2009, 27:542-549. 10.1200/JCO.2008.17.1462, 19075277.
27. Meijer-van ME, Look MP, Peters HA, Schmitt M, Brunner N, Harbeck N, Klijn JG, Foekens JA. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease. Cancer Res 2004, 64:4563-4568. 10.1158/0008-5472.CAN-03-3848, 15231667.
28. Martens JW, Nimmrich I, Koenig T, Look MP, Harbeck N, Model F, Kluth A, Bolt-de J, Sieuwerts AM, Portengen H, Meijer-Van ME, Piepenbrock C, Olek A, Höfler H, Kiechle M, Klijn JG, Schmitt M, Maier S, Foekens JA. Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res 2005, 65:4101-4117. 10.1158/0008-5472.CAN-05-0064, 15899800.